2nd Circ. Nixes RxUSA's Bid To Revive Antitrust Suit
A panel of the U.S. Court of Appeals for the Second Circuit issued a summary order Monday affirming a dismissal of the suit and finding that RxUSA can't support Sherman Act claims.
The court ruled that Long Island, N.Y.-based RxUSA failed to adequately allege claims of anti-monopolization and restraint of trade against groups of major drug manufacturers, including...
Already a subscriber? Click here to login